CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 178 enrolled
Drug / intervention
peginterferon alfa 2a (pegasys) +1 moredrug
Likely dose
peginterferon alfa-2a (pegasys) 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01378104
NCT01378104Phase 4Completed
CompareCT.gov

The Response of Reducing Dose of Peginterferon Alfa-2a in Koreans With Chronic Hepatitis C Genotype 1; Randomized Controlled Multicenter Study 100% Versus 80%

The Catholic University of Korea·interventional·Posted Jun 22, 2011·Updated Mar 8, 2013

In Brief

A Phase 4 clinical trial evaluating peginterferon alfa 2a (pegasys) and peginterferon alfa-2a (pegasys) for Sustained Virologic Response and IL28B Polymorphism. Completed, enrolled 178 participants across 14 sites.

Detailed Summary

1. Randomized controlled multicenter study 2. The response of reducing dose of peginterferon alfa-2a in Koreans with chronic hepatitis C genotype 1 3. IL28B polymorphism in Koreans with CHC

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSustained Virologic Response, IL28B Polymorphism
CountriesSouth Korea
CollaboratorsUlsan University Hospital, National Health Insurance Service Ilsan Hospital, Inje University, Soonchunhyang University Hospital, Yonsei University, Chungnam National University, Keimyung University, Kyungpook National University Hospital, Konyang University Hospital, Inha University Hospital, Hallym University Medical Center

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 22, 2011
Enrollment StartOct 1, 2008
Primary CompletionSep 1, 2011
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 15.0 years ago

Interventions

peginterferon alfa 2a (pegasys)drug

dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable

peginterferon alfa-2a (pegasys)drug

These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.